AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca plc (NYSE: AZN) faced a clinical setback in a study evaluating a combo drug regimen in non-small cell lung cancer, or NSCLC.

AstraZeneca's Drug Combo To Treat Non-Small Cell Lung Cancer Stumbles In Late-Stage Study

AstraZeneca announced that it had achieved statistically significant overall survival, a first in the 1st-line locally advanced or metastatic NSCLC population with EGFR mutations segment.

AstraZeneca's Latest Lung Cancer Data Sets It Apart Because Of Its Targeted Approach To Treatment

Starpharma’s VivaGel BV products enter Australian and Asian markets.

Starpharma Needs Patience But Upside Is Interesting

The Breakthrough Therapy Designation (BTD) to AstraZeneca's (AZN) Calquence is based on positive interim data from two phase III studies.

AstraZeneca Calquence Gets FDA's Breakthrough Status for CLL

Baxter

Zoetis

They're flying high right now. But are these three healthcare stocks smart picks?

3 Healthcare Stocks at All-Time Highs: Are They Buys?

Positive top-line results from a competitor’s prostate cancer drug trial led Bank of America to downgrade Clovis Oncology Inc (NASDAQ: CLVS).

AstraZeneca Success On Prostate Cancer Drug Lowers Enthusiasm For Clovis

Amgen

Eli Lilly

These industry giants could make big moves after this year's World Conference on Lung Cancer.

3 Lung Cancer Stocks That Could Soar in September

Abbott Labs

Johnson & Johnson

Merck

Novartis

Pfizer

Roche Holding AG

Thermo Fisher Scientific

The fight against cancer is a big battle. And these 10 companies are among the biggest combatants you can invest in.

10 Biggest Cancer-Fighting Stocks

AstraZeneca (AZN) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

AstraZeneca (AZN) Jumps: Stock Rises 5.7%

AstraZeneca PLC (AZN) CEO Pascal Soriot on Q2 2019 Results - Earnings Call Transcript

Nokia

Ambev

Solid earnings lifted some stocks despite a big market downturn.

Why AstraZeneca, Ambev, and Nokia Jumped Today

AstraZeneca (AZN) beats estimates for earnings and sales. New drugs, mainly cancer medicines, lead to high product sales.

AstraZeneca (AZN) Q2 Earnings Top, '19 Product Sales View Up

Bristol-Myers

Bristol earnings and sales topped estimates Thursday, but Bristol stock fell early. AstraZeneca stock popped after the pharmaceutical company beat expectations and raised its sales outlook.

Pharma Giants Top Second-Quarter Estimates, But Only One Stock Pops

AstraZeneca's (AZN) SGLT2 inhibitor, Farxiga, gets CRL from the FDA for a regulatory application seeking label expansion as a treatment for type I diabetes.

AstraZeneca's Farxiga Gets CRL from FDA for Type I Diabetes

The FDA assigns an orphan drug designation to AstraZeneca's (AZN) Imfinzi for the treatment of small cell lung cancer, the most aggressive type of the ailment.

AstraZeneca's Imfinzi Gains Orphan Drug Status for SCLC

AstraZeneca (AZN) gets positive CHMP opinion for self-administration option for Fasenra and the Fasenra pen and to include outcomes data on Forxiga???s label.

AstraZeneca Gets CHMP Nod for Forxiga/Fasenra Expanded Label

AstraZeneca (AZN) announces positive overall survival results from the phase III CASPIAN study evaluating Imfinzi in first-line extensive-stage SCLC.

AstraZeneca's Imfinzi Meets Endpoint in Lung Cancer Study

Sanofi

According to the GuruFocus All-in-One Screener, the following companies look cheap since they are trading with low price-sales ratios.

Stocks With Low Price-Sales Ratios

AstraZeneca achieved positive data in the phase 3 ASCEND study which used Calquence to treat patients with relapsed/refractory chronic lymphocytic leukemia.

AstraZeneca Calquence CLL Data Sets It Up For Regulatory Submissions In 2019

AstraZeneca (AZN) gets approval in Japan for PT010, its triple-combo inhaler and Bevespi Aerosphere, a fixed-dose LABA/LAMA inhaler, both to treat COPD.

AstraZeneca's Triple-Combo COPD Inhaler Gets Japan's Nod

AstraZeneca (AZN) and Merck's PARP inhibitor, Lynparza, gets approval in EU as a front-line therapy for BRCA-mutated advanced ovarian cancer.

AstraZeneca/Merck's Lynparza Wins EU Nod for First-Line Use

AstraZeneca's (AZN) Calquence monotherapy prolongs progression-free survival significantly in relapsed or refractory CLL patients compared to Roche's Rituxan.

AstraZeneca Gives Detailed Data From Calquence Leukemia Study

Biohaven Pharmaceutical Hld

Biogen

Alzheimer's treatment continues to confound biotech companies in the wake of Biogen and Eisai's decision to terminate two late-stage tests. But scientists say there's hope in new theories.

Why Alzheimer's Treatment Hopes Endure Despite High-Profile Drug Failures

AstraZeneca's (AZN) lymphoma drug, Calquence, meets the primary endpoint and a key secondary one in a phase III study for the first-line treatment of chronic lymphocytic leukaemia.

AstraZeneca's Calquence Meets Endpoint in 2nd CLL Study

Pharma bigwigs present data from cancer studies at ASCO. Lilly's (LLY) CGRP Emgality gets FDA approval for episodic cluster headache in adults.

News for AstraZeneca Stock (AZN)